Goldman Sachs Group Inc Entrada Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 92,540 shares of TRDA stock, worth $841,188. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,540
Previous 285,272
67.56%
Holding current value
$841,188
Previous $4.93 Million
83.05%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding TRDA
# of Institutions
109Shares Held
27.7MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$44.2 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$40.1 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$39.8 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$26.4 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$18.9 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $285M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...